Evidence map›Paper›PMID 31363375›Full record

ArticleExperimental and therapeutic medicine2019

Effect of miR-140-5p on the regulation of proliferation and apoptosis in NSCLC and its underlying mechanism.

Wenwen Zhou, Xiaoyu Wang, Duanduan Yin, Lei Xue, Zhongfeng Ma, Zhenzhen Wang, Qianyi Zhang, Zishu Zhao, Haixia Wang, Yan Sun and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Experimental and therapeutic medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Wenwen ZhouDepartment of Oncology, Qinhuangdao First People's Hospital, Qinhuangdao, Hebei 066000, P.R. China.
Xiaoyu WangFoundation and Clinic of Malignant Tumor, Postgraduate College, Chengde Medical University, Chengde, Hebei 067000, P.R. China.
Duanduan YinDepartment of Oncology, Qinhuangdao First People's Hospital, Qinhuangdao, Hebei 066000, P.R. China.
Lei XueDepartment of Oncology, Qinhuangdao First People's Hospital, Qinhuangdao, Hebei 066000, P.R. China.
Zhongfeng MaDepartment of Oncology, Qinhuangdao First People's Hospital, Qinhuangdao, Hebei 066000, P.R. China.
Zhenzhen WangDepartment of Oncology, Qinhuangdao First People's Hospital, Qinhuangdao, Hebei 066000, P.R. China.
Qianyi ZhangDivision of Pharmacy, University of Tasmania, Hobart, Tasmania 7005, Australia.
Zishu ZhaoFoundation and Clinic of Malignant Tumor, Postgraduate College, Chengde Medical University, Chengde, Hebei 067000, P.R. China.
Haixia WangFoundation and Clinic of Malignant Tumor, Postgraduate College, Hebei Medical University, Shijiazhuang, Hebei 051117, P.R. China.
Yan SunDepartment of Oncology, Qinhuangdao First People's Hospital, Qinhuangdao, Hebei 066000, P.R. China.
Yanhong YangDepartment of Oncology, Qinhuangdao First People's Hospital, Qinhuangdao, Hebei 066000, P.R. China.
First Hospital of Qinhuangdao · CNChengde Medical University · CNHebei Medical University · CNUniversity of Tasmania · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer accounting for ~80% of lung cancer cases. According to novel research, numerous microRNAs (miRs) have been suggested to function as important regulators of cancer. In addition, the expression of miR-140-5p is decreased in patients with NSCLC. Therefore, it is important to further elucidate the role of miR-140-5p in NSCLC. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used in order to investigate the expression of miR-140-5p in NSCLC tissues and matched normal tissues and to determine miR-140-5p levels following transfection with mimics into A549 lung cancer cells. Targetscan software was used to predict the oncogene target of miR-140-5p. This analysis revealed that YES proto-oncogene 1 (YES1) includes a target site for miR-140-5p binding. The results revealed that YES1 is a potential target gene of miR-140-5p, and this was further confirmed by the results of luciferase reporter assays, which demonstrated that miR-140-5p directly targeted the predicted binding site in the 3'-untranslated region of YES1. Cell Counting Kit-8 (CCK-8) and flow cytometry assays were performed to determine the levels of cell viability and apoptosis. Western blot assays was performed to investigate the expression levels of YES1 and proteins associated with apoptosis in A549 cells following transfection. The results revealed that miR-140-5p expression was significantly downregulated in NSCLC tissues compared with matched normal tissues. The expression of miR-140-5p was significantly increased following transfection with miR-140-5p mimics. The results of CCK-8 and flow cytometry assays indicated that miR-140-5p inhibited proliferation and induced apoptosis of tumor cells. Western blot analysis and RT-qPCR revealed that YES1 and B-cell lymphoma 2 (Bcl-2) mRNA and protein expression levels were markedly decreased in A549 cells, while Bcl-2 associated X (Bax) and caspase-3 expression levels increased significantly following transfection with miR-140-5p mimics compared with the negative control group. In conclusion, miR-140-5p may induce apoptosis in A549 cells by targeting YES1 and regulating the expression of apoptosis-associated proteins Bcl-2, Bax and caspase-3.

Indexed as

apoptosismicroRNA-140-5pnon-small cell lung cancerYES proto-oncogene 1

Identifiers

PMID31363375
PMCPMC6614735
OpenAlexW2952657970

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.